{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:59:20Z","timestamp":1793149160942,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.intimp.2022.109628","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T23:40:47Z","timestamp":1672098047000},"page":"109628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Thymosin \u03b24 and the anti-fibrotic switch"],"prefix":"10.1016","volume":"115","author":[{"given":"Hynda K.","family":"Kleinman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Kulik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan L.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.109628_b0005","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.immuni.2016.02.015","article-title":"Macrophages in tissue repair, regeneration and fibrosis","volume":"44","author":"Wynn","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2022.109628_b0010","doi-asserted-by":"crossref","unstructured":"L.A. Murtha, M.J. Schuliga, N.S. Mabotuwana, S.A. Hardy, D.W. Waters, J.K. Burgess, D.A. Knight, A.J. Boyle, The process of mechanisms of cardiac and pulmonary fibrosis, Frontiers Physiol. 8 (2017) Article 777 10.3389\/fphus.2017.00777.","DOI":"10.3389\/fphys.2017.00777"},{"key":"10.1016\/j.intimp.2022.109628_b0015","doi-asserted-by":"crossref","unstructured":"C. Gu, X. Shi, X. Dang, J. Chen, C. Chen, Y. Chen, X. Pan, T. Huang, Identification of common genes and pathways in eight fibrotic diseases. Frontiers in Genetics 11 (2021) Article 27396, 10.3389\/fgene.2020.627396.","DOI":"10.3389\/fgene.2020.627396"},{"key":"10.1016\/j.intimp.2022.109628_b0020","doi-asserted-by":"crossref","unstructured":"S. Hinderer, K. Schenke-Layland K, Cardiac fibrosis-A short review of causes and therapeutic strategies. Adv. Drug Devel. Rev. 146 (2019) 77-82 10.1016\/j.addr.2019.05.011.","DOI":"10.1016\/j.addr.2019.05.011"},{"key":"10.1016\/j.intimp.2022.109628_b0025","doi-asserted-by":"crossref","unstructured":"A. Goldstein, H.K. Kleinman, Advances in the basic and clinical applications of thymosin beta 4, Expert Opin Biol. Ther. 15(2015): suppl 1: S139-145. 10.1517\/14712598.2015.1011617.","DOI":"10.1517\/14712598.2015.1011617"},{"key":"10.1016\/j.intimp.2022.109628_b0030","doi-asserted-by":"crossref","unstructured":"H.P. Ehrlich, W.W. Hazard, III, Thymosin \u03b24 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts. Ann. N.Y. Acad. Sci. 1194 (2010) 118-124. 10.1111\/j.1749-6632.2010.05483.x.","DOI":"10.1111\/j.1749-6632.2010.05483.x"},{"key":"10.1016\/j.intimp.2022.109628_b0035","doi-asserted-by":"crossref","unstructured":"Y. Xing, Y. Ye, H. Zuo, Y. Li, Progress on the function and application of thymosin beta 4, Frontiers in Endocrinology 12 (2021) Article 767785 10.3389%2Ffendo.2021.767785.","DOI":"10.3389\/fendo.2021.767785"},{"key":"10.1016\/j.intimp.2022.109628_b0040","doi-asserted-by":"crossref","unstructured":"M. Badamchian, A. Ali, H. Damavandy, D. Wadhwa, B. Katz, A.L. Goldstein, Identification and quantitation of thymosin beta 4 in human tears and saliva. Ann. N.Y. Acad. Sci. 1112 (2007) 458-65 10.1196\/annals.1415.046.","DOI":"10.1196\/annals.1415.046"},{"key":"10.1016\/j.intimp.2022.109628_b0045","doi-asserted-by":"crossref","unstructured":"A. Bi\u00e7er , \u00d6. Karakurt, R. Akdemir, G. Erden, A. Yildiz, \u00d6. \u00d6zcan, Y. Sezen, S. A\u00e7ikel, H. Kili\u00e7, R. Demirba\u011f, Thymosin beta 4 is associated with collateral development in coronary artery disease. Cand. J. clin. Lab Invest. 71 (2011) 625-30 10.3109\/00365513.2011.599417.","DOI":"10.3109\/00365513.2011.599417"},{"key":"10.1016\/j.intimp.2022.109628_b0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ab.2010.03.029","article-title":"Quantification of thymosin b4 in human cerebrospinal fluid using matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry","volume":"402","author":"Urso","year":"2010","journal-title":"Analytical Biochem."},{"key":"10.1016\/j.intimp.2022.109628_b0055","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1432-1033.1996.0086n.x","article-title":"Biochemical and antibacterial analysis of human wound and blister fluid","volume":"237","author":"Frohm","year":"1996","journal-title":"Eur J. Biochem."},{"key":"10.1016\/j.intimp.2022.109628_b0060","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/14712598.2012.634793","article-title":"Thymosin beta 4: A multifunctional regenerative peptide. Basic and clinical applications","volume":"12","author":"Goldstein","year":"2012","journal-title":"Exp. Opin. Biol. Ther."},{"issue":"sup1","key":"10.1016\/j.intimp.2022.109628_b0065","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/14712598.2015.1026804","article-title":"Effects of thymosin \u03b24 and its N-terminal fragment Ac-SDKP on TGF-\u03b2-treated human lung fibroblasts and in the mouse model of bleomycin-induced lung fibrosis","volume":"15","author":"Conte","year":"2015","journal-title":"Exp. Opin. Biol Ther."},{"key":"10.1016\/j.intimp.2022.109628_b0070","doi-asserted-by":"crossref","unstructured":"G. Sosne, P. Qui, A.L. Goldstein, Biological activities of thymosin beta4 defined by active sites in short peptide sequences, FASEB J. 24(2010):2144-51 10.1096\/fj.09-142307 doi: 10.1096\/fj.09-142307.","DOI":"10.1096\/fj.09-142307"},{"key":"10.1016\/j.intimp.2022.109628_b0075","doi-asserted-by":"crossref","unstructured":"H. Li, Q. Li, X. Zhang, X. Zheng, Q. Zhang, Thymosin beta 4 suppressed CCL4-induced murine hepatic fibrosis by down-regulating transforming growth factor beta receptor-II, J. Gene Med. (2018) 20e3043 10.1002\/jgm.3043.","DOI":"10.1002\/jgm.3043"},{"key":"10.1016\/j.intimp.2022.109628_b0080","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10753-021-01528-6","article-title":"Thymosin beta 4 suppresses LPS-Induced murine lung fibrosis by attenuating oxidative injury and alleviating inflammation","volume":"45","author":"Tian","year":"2022","journal-title":"Inflammation"},{"key":"10.1016\/j.intimp.2022.109628_b0085","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1465-9921-12-22","article-title":"Beta thymosins and interstitial lung disease: Study of a scleroderma cohort with a one year follow up","volume":"12","author":"De Santis","year":"2011","journal-title":"Respir. Res."},{"key":"10.1016\/j.intimp.2022.109628_b0090","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3748\/wjg.v16.i5.625","article-title":"Serum thymosin beta4 levels in patients with hepatitis B virus-related liver failure","volume":"16","author":"Han","year":"2010","journal-title":"World J. Gastroenerol."},{"key":"10.1016\/j.intimp.2022.109628_b0095","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/bs.vh.2016.04.005","article-title":"Thymosin beta 4 promotes dermal healing","volume":"102","author":"Kleinman","year":"2016","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.intimp.2022.109628_b0100","doi-asserted-by":"crossref","first-page":"10624","DOI":"10.3390\/ijms160510624","article-title":"The potential role of thymosin beta 4 in liver fibrosis","volume":"16","author":"Kim","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2022.109628_b0105","doi-asserted-by":"crossref","unstructured":"R. Shah, K. Reyes-Gordillo, M. Rojkind, Thymosin beta 4 inhibits PDGF-BB induced activation, proliferation, and migration of human hepatic stellate cells via its actin-binding domain, Expert Opin. Biol. Therapy.18(2018) sup1, 177-194 10.1080%2F14712598.2018.1478961.","DOI":"10.1080\/14712598.2018.1478961"},{"key":"10.1016\/j.intimp.2022.109628_b0110","first-page":"324","article-title":"thymosin beta 4 alleviates cholestatic liver fibrosis in mice through downregulating PDGF\/PDGFR and TGF beta\/Smad pathways","volume":"52","author":"Chen","year":"2020","journal-title":"Liver, Pancreas and Biliary Tract"},{"key":"10.1016\/j.intimp.2022.109628_b0115","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.bbrc.2017.09.156","article-title":"Thymosin beta 4 attenuates liver fibrosis via Notch signaling","volume":"493","author":"Hong","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2022.109628_b0120","doi-asserted-by":"crossref","unstructured":"K. Reyes-Gordillo, R. Shah, A. Propraitiloff, A. Hindle, F. Brody, M. Rojkind, Thymosin beta 4 blunts PDGF-dependent phosphorylation and binding of AKT to actin in hepatic stellate cells, American J. Pathol. 178(2011) 2100-2108 10.1016%2Fj.ajpath.2011.01.025.","DOI":"10.1016\/j.ajpath.2011.01.025"},{"key":"10.1016\/j.intimp.2022.109628_b0125","doi-asserted-by":"crossref","unstructured":"L. Zhu, M. Cheng, Y. Liu, Y. Yao, Z. Zhu, B. Zhang, Q. Mou, Y. Cheng, Thymosin beta 4 inhibits proliferation and induces apoptosis of hepatic stellate cells throughPI3K\/AKT pathway, Oncotarget 8(2017)68847-68853 10.18632%2Foncotarget.18748.","DOI":"10.18632\/oncotarget.18748"},{"key":"10.1016\/j.intimp.2022.109628_b0130","doi-asserted-by":"crossref","unstructured":"P. Qiu, M.K. Wheater, Y. Qiu Y, G.Sosne, Thymosin beta4 inhibits TNF-alpha-induced NF-KappaB activation, Il-8 expression, and the sensitizing effects of its partners PINCH-1 and ILK, FASEB J. 25(2011) 1815-26 10.1096\/fj.10-167940.","DOI":"10.1096\/fj.10-167940"},{"issue":"5","key":"10.1016\/j.intimp.2022.109628_b0135","doi-asserted-by":"crossref","first-page":"e20184","DOI":"10.1371\/journal.pone.0020184","article-title":"Significance of thymosin beta 4 and implication of PINCH-1-ILK-alpha PARVIN (PIP) complex and human dilated cardiomyopathy","volume":"6","author":"Sopko","year":"2011","journal-title":"PLOS One"},{"key":"10.1016\/j.intimp.2022.109628_b0140","doi-asserted-by":"crossref","first-page":"10500","DOI":"10.1038\/s41598-018-28861-5","article-title":"RGN-259 (thymosin \u03b24) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model","volume":"8","author":"Kim","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2022.109628_b0145","doi-asserted-by":"crossref","unstructured":"G. Renga, V. Oikonomou, C. Stincardini, M. Pariano, M. Borghi, M. Constantini, Thymosin beta 4 limits inflammation through autophagy, Exp. Opin. Biol. Therapy 18(2018)sup1. 10.1080\/14712598.2018.1473854.","DOI":"10.1080\/14712598.2018.1473854"},{"key":"10.1016\/j.intimp.2022.109628_b0150","unstructured":"C. Wei, S. Kumar, I.K. Kim, S. Gupta, Thymosin beta 4 protects cardiomyocytes from oxidative stress by targeting anti-oxidative enzymes and anti-apoptotic genes, PLOS One Nov 20;9(11) (2011):e110598 10.1371\/journal.pone.0110598. eCollection 2014."},{"key":"10.1016\/j.intimp.2022.109628_b0155","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1139\/cjpp-2018-0570","article-title":"Thymosin beta4-Ac-SDKP pathway: Any relevance for the cardiovascular system","volume":"97","author":"Kassem","year":"2019","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109628_b0160","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1161\/HYPERTENSIONAHA.115.05970","article-title":"Renal protective effect of N-acetyl-seryl- aspartyl-lysyl-proline in Dahl salt-sensitive rats","volume":"66","author":"Worou","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.intimp.2022.109628_b0165","doi-asserted-by":"crossref","first-page":"F195","DOI":"10.1152\/ajprenal.00270.2018","article-title":"Renal release of N-acetyl-seryl-aspartyl-lysyl-proline is part of an antifibrotic peptidergic system in the kidney","volume":"316","author":"Romero","year":"2019","journal-title":"Am. J. Physiol. Renal Physion."},{"key":"10.1016\/j.intimp.2022.109628_b0170","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/ki.2013.209","article-title":"Thymosin beta4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis","volume":"84","author":"Zuo","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.intimp.2022.109628_b0175","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.106.084103","article-title":"Decreased endogenous levels of Ac-SDKP promote organ fibrosis","volume":"50","author":"Cavasin","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.intimp.2022.109628_b0180","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1161\/01.HYP.0000126172.01673.84","article-title":"Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP","volume":"43","author":"Cavasin","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.intimp.2022.109628_b0185","doi-asserted-by":"crossref","unstructured":"C. Chiurchiu, G. Remuzzi, P. Ruggenenti, Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses, J. Am. Soc. Nephrol. 16 (2005) Suppl 1 S58\u2013S63 10. 1681\/ASN.2004110968.","DOI":"10.1681\/ASN.2004110968"},{"key":"10.1016\/j.intimp.2022.109628_b0190","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0022-3565(24)35199-7","article-title":"Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in rats","volume":"291","author":"Junot","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.intimp.2022.109628_b0195","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00004872-200403000-00023","article-title":"Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension","volume":"22","author":"Rasoul","year":"2004","journal-title":"J Hyper- tens"},{"key":"10.1016\/j.intimp.2022.109628_b0200","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/labinvest.2012.2","article-title":"Loss of angiotensin-converting enzyme 2 enhances TGB-Beta\/Smad-mediated renal fibrosis and NF-Kappa B driven renal inflammation in a mouse model of obstructive nephropathy","volume":"92","author":"Liu","year":"2012","journal-title":"Lab. Invest."},{"key":"10.1016\/j.intimp.2022.109628_b0205","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00109-012-0859-2","article-title":"Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury","volume":"90","author":"Rey-Parra","year":"2012","journal-title":"Mol. Med. (Berl)"},{"key":"10.1016\/j.intimp.2022.109628_b0210","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1111\/bph.14489","article-title":"Angiotensin-converting enzyme inhibitor works as a scar formation inhibitor by down-regulating Smad and TGF-\u03b2-activated kinase 1 (TAK1) pathways in mice","volume":"175","author":"Tan","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.intimp.2022.109628_b0215","doi-asserted-by":"crossref","first-page":"H1357","DOI":"10.1152\/ajpheart.00464.2009","article-title":"Ac-SDKP inhibits transforming growth factor-alpha1-induced differentiation of human cardiac fibroblasts into myofibroblasts","volume":"298","author":"Peng","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.intimp.2022.109628_b0220","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/01.HYP.0000107777.91185.89","article-title":"Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction","volume":"43","author":"Yang","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.intimp.2022.109628_b0225","doi-asserted-by":"crossref","first-page":"F1146","DOI":"10.1152\/ajprenal.00039.2015","article-title":"N-Acetyl-Seryl-Aspartyl- Lysyl-Proline: mechanisms of renal protection in mouse model of systemic lupus erythematosus","volume":"308","author":"Liao","year":"2015","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.intimp.2022.109628_b0230","doi-asserted-by":"crossref","unstructured":"T.D. Liao, X.P. Yang, M. D\u2019Ambrosio, Y. Zhang, N.E. Rhaleb, O.A. Carretero, N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dys-function in hypertensive rats with reduced renal mass: council for high blood pressure research, Hypertension 55(2010) 459\u2013467 10.1161\/ HYPERTENSIONAHA.109.144568.","DOI":"10.1161\/HYPERTENSIONAHA.109.144568"},{"key":"10.1016\/j.intimp.2022.109628_b0235","doi-asserted-by":"crossref","unstructured":"U.C. Sharma, S.D. Sonkawade, J.A. Spernyak, S. Sexton, J. Nguyen, et al, A small peptide Ac-SDKP inhibits radiation-induced cardiomyopathy, Circ. Heart Fail 11(8) (2018):e004867 10.1161\/CIRCHEARTFAILURE.117.004867.","DOI":"10.1161\/CIRCHEARTFAILURE.117.004867"},{"key":"10.1016\/j.intimp.2022.109628_b0240","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/jdi.13219","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline is a valuable endogenour antfibrotic peptide for kidney fibrosis in daibetes: An update and translational aspects","volume":"11","author":"Kanasaki","year":"2020","journal-title":"J Diabetes Investig."},{"issue":"8","key":"10.1016\/j.intimp.2022.109628_b0245","doi-asserted-by":"crossref","first-page":"e2965","DOI":"10.1038\/cddis.2017.353","article-title":"FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N-acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway","volume":"3","author":"Li","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2022.109628_b0250","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1161\/HYPERTENSIONAHA.120.15587","article-title":"Endothelial FGFR1 (fibroblast growth factor receptor 1) deficiency contributes differential fibrogenic effects in kidney and heart of diabetic mice","volume":"76","author":"Li","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.intimp.2022.109628_b0255","doi-asserted-by":"crossref","unstructured":"H. Li, Q. Li, X. Zhang, X. Zheng, Q. Zhang, Z. Hao, Thymosin \u03b24 suppresses CCl4-induced murine hepatic fibrosis by down-regulating transforming growth factor \u03b2 receptor-II. The Journal of Gene Medicine, 20 (2018), e3043. 10.1002\/jgm.3043.","DOI":"10.1002\/jgm.3043"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922011134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922011134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T09:04:44Z","timestamp":1736413484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922011134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":51,"alternative-id":["S1567576922011134"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109628","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thymosin \u03b24 and the anti-fibrotic switch","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"109628"}}